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Commentary on “Inhibiting inflammation with Myeloid cell-specific nanobiologics 
promotes organ transplant acceptance” by Braza et al, Immunity 2018   
 
Organ transplantation has proven to be very effective in a variety of end stage diseases. 
Immunosuppressive agents prescribed  to patients modestly improves graft survival but long 
term use can have detrimental side effects, leaving patients with increased risk of infection, 
cancer, and metabolic toxicity1. Strategies targeting adaptive immune cell tolerance 
induction have proven promising2, however long term graft survival rates still remain sub-
optimal. More recently innate immune cells, including macrophages, NK cells and 
monocytes have been identified as key players in the initiation of allograft rejection3, 4. The 
mechanisms by which macrophages mediate graft loss remain poorly understood.  
Recently, a study by Braza et al.,5 identified a macrophage activation pathway linked to 
allograft rejection. The authors utilised a novel myeloid-specific nanoimmunotherapy to 
target graft infiltrating macrophages to promote long term organ transplant acceptance. Pro-
inflammatory activation of macrophages by danger associated molecular patterns (DAMPs) 
vimentin and high mobility group box 1 (HMGB1) by  dectin-1 and TLR4 activation has been 
previously shown6, 7. Using an experimental heart transplantation mouse model, Braza et al., 
found both vimentin and HMGB1 were upregulated in allograft infiltrating macrophages; 
raising the question whether  these targets could promote “trained immunity”. Innate immune 
cells can acquire trained immunity or “innate immune memory”,  whereby secondary non-
specific challenge, after pre-exposure to certain inflammatory stimuli triggers epigenetic and 
metabolic changes, enhancing pro-inflammatory responses8. Monocytes pre-exposed to 
vimentin, followed by re-stimulation with HMGB1, increased  pro-inflammatory IL-6 and 
TNFα production in vitro. Graft-infiltrating macrophages from dectin-1 and TLR4 deficient 
mouse heart allografts produced significantly lower levels of IL-6 and TNFα  following ex-
vivo stimulation.  
To target trained macrophages therapeutically, Braza et al., utilised myeloid specific high-
density lipoproteins (HDL) nanobiologics9. The authors armed their nanobiologics with 
rapamycin, an mTOR inhibitor (termed mTORi-HDL), which has been shown to inhibit 
myeloid cell activation and pro-inflammatory cytokine production10. Heart allografts in 
recipient mice were shown to accumulate mTORi-HDL and its uptake preferentially by 
myeloid cells, namely macrophages. A treatment regime of three intravenous doses of 
mTORi-HDL was sufficient to prolong graft survival, compared to placebo control or mice 
treated with oral rapamycin. Following ex vivo stimulation it was shown that these 
macrophages had a marked reduction in pro-inflammatory cytokine production, suggesting 
trained macrophage responses were impaired because of mTORi-HDL treatment. Recipient 
allografts, blood and spleen were shown to have increased numbers of Ly6CLo 
macrophages, reported to have anti-inflammatory properties. The authors confirmed that 
Ly6CLo macrophages  inhibited T cell proliferation and promoted regulatory T cell (Treg) 
expansion in vitro, in addition, mTORi-HDL allografts were shown to have significantly 
elevated Tregs counts. Irrespective of mTORi-HDL treatment, Ly6CLo macrophage depletion 
prior to transplantation resulted in early graft rejection. Allograft survival was restored 
following adoptive transfer of wild-type monocytes, reinforcing the view that the mTORi-HDL 
therapy requires Ly6CLo regulatory macrophages for successful organ transplant 
acceptance. Finally, the authors evaluated the impact of combinational therapy with mTORi-
HDL and a CD40-CD40L targeting nanbiologic, TRAF6i-HDL11. They found that short-term 
combination therapy with mTORi-HDL/ TRAF6i-HDL synergistically promoted long-term 
allograft survival, and significantly outperformed either monotherapy.         
The study by Braza et al., clearly highlights the importance of innate immune signalling in 
driving trained immunity and excessive inflammation. Taking atherosclerosis as an example, 
Bekkering et al.,12 found that exposing monocytes to a low concentration of oxLDL  drove a 
trained proatherogenic macrophage phenotype characterised by increased pro-inflammatory 
cytokine production and foam cell formation. A review by Zhang and colleagues13 
emphasised the importance of  trained macrophage activation pathways in pathological 
conditions such as cardiac remodelling and ischaemic heart disease. A recent review by 
Kusters and colleagues14 reiterated the importance of immune checkpoint molecules and 
their potential as therapeutic targets in atherosclerosis. The concept of targeting immune 
checkpoint molecules,  such as CD40-CD40L, as chosen by Braza et al., or others, like 
CD80/86-CD28, is not a novel concept in of itself. However, the use of nanobiologics to 
successfully administer high local doses of immunosuppressive agents while limiting 
systemic toxicity proves to be a very attractive modality of treatment and  could very well 
breathe life into current treatment regimens and combinatorial therapies in the treatment of 
multiple chronic inflammatory diseases.  
 
Funding  
The author would like to acknowledge support from the Birmingham Fellowship scheme and 
Academy of Medical Sciences Springboard scheme (SBF003\1156) 
 
References 
1. Fishman JA. Infection in Organ Transplantation. Am J Transplant. 2017;17:856-879. 
2. Page EK, Dar WA and Knechtle SJ. Tolerogenic therapies in transplantation. Front Immunol. 
2012;3:198. 
3. Liu W, Xiao X, Demirci G, Madsen J and Li XC. Innate NK cells and macrophages recognize 
and reject allogeneic nonself in vivo via different mechanisms. J Immunol. 2012;188:2703-11. 
4. Oberbarnscheidt MH, Zeng Q, Li Q, Dai H, Williams AL, Shlomchik WD, Rothstein DM and 
Lakkis FG. Non-self recognition by monocytes initiates allograft rejection. J Clin Invest. 
2014;124:3579-89. 
5. Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Perez-Medina C, 
Conde P, Garcia MR, Gonzalez-Perez M, Brahmachary M, Fay F, Kluza E, Kossatz S, Dress RJ, Salem F, 
Rialdi A, Reiner T, Boros P, Strijkers GJ, Calcagno CC, Ginhoux F, Marazzi I, Lutgens E, Nicolaes GAF, 
Weber C, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WJM 
and Ochando J. Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ 
Transplant Acceptance. Immunity. 2018;49:819-828 e6. 
6. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-
Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U and Tracey KJ. A critical 
cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine 
release. Proc Natl Acad Sci U S A. 2010;107:11942-7. 
7. Thiagarajan PS, Yakubenko VP, Elsori DH, Yadav SP, Willard B, Tan CD, Rodriguez ER, 
Febbraio M and Cathcart MK. Vimentin is an endogenous ligand for the pattern recognition receptor 
Dectin-1. Cardiovasc Res. 2013;99:494-504. 
8. Netea MG and van der Meer JW. Trained Immunity: An Ancient Way of Remembering. Cell 
Host Microbe. 2017;21:297-300. 
9. Mulder WJM, van Leent MMT, Lameijer M, Fisher EA, Fayad ZA and Perez-Medina C. High-
Density Lipoprotein Nanobiologics for Precision Medicine. Acc Chem Res. 2018;51:127-137. 
10. Ballou LM and Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1:27-36. 
11. Guilliams M, Mildner A and Yona S. Developmental and Functional Heterogeneity of 
Monocytes. Immunity. 2018;49:595-613. 
12. Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG and Riksen NP. Oxidized low-
density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation 
via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol. 2014;34:1731-8. 
13. Zhang Y, Huang Z and Li H. Insights into innate immune signalling in controlling cardiac 
remodelling. Cardiovasc Res. 2017;113:1538-1550. 
14. Kusters PJH, Lutgens E and Seijkens TTP. Exploring immune checkpoints as potential 
therapeutic targets in atherosclerosis. Cardiovasc Res. 2018;114:368-377. 
 
